• Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennett, C. & Engert, A. (2005a) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. Journal of the National Cancer Institute, 97, 489498.
  • Bohlius, J., Wilson, J., Bayliss, S., Djulbegovic, B., Hyde, C., Trelle, S., Weingart, O., Brunskill, S., Sandercock, J., Seidenfeld, J., Piper, M., Langensiepen, S., Schwarzer, G., Bennett, C. & Engert, A. (2005b) Epoetin and darbepoetin to treat cancer patients: updated meta-analysis results (abstract). Blood, 106, 222a, 751.
  • Boogaerts, M., Coiffier, B. & Kainz, C. (2003) Impact of epoetin beta on quality of life in patients with malignant disease. British Journal of Cancer, 88, 988995.
  • Brandt, M., Lanzendörfer, M., Frische, J., Haselbeck, A. & Jarsch, M. (2006) Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells (abstract). Nephrology, Dialysis, Transplantation, 21(Suppl. 4), iv9, SO018.
  • Canon, J.L., Vansteenkiste, J., Bodoky, G., Mateos, M.V., Bastit, L., Ferreira, I., Rossi, G. & Amado, R.G. (2006) Randomized, double-blind, active-controlled trial of every 3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. Journal of the National Cancer Institute, 98, 273284.
  • Cazzola, M., Beguin, Y., Kloczko, J., Spicka, I. & Coiffier, B. (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 122, 386393.
  • Cella, D. (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Seminars in Oncology, 25(Suppl. 7), 4346.
  • Coiffier, B., Boogaerts, M., Aapro, M., Huber, M. & Burger, H.-U. (2004) Thromboembolic events in patients with cancer treated with epoetin beta: A meta-analysis of controlled clinical trials (abstract). Annals of Oncology, 15(Suppl. 3), iii221, 840P.
  • Dougherty, F.C., Reigner, B., Jordan, P. & Pannier, A. (2004) Continuous Erythropoiesis Receptor Activator (C.E.R.A.) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers (abstract). Annals of Oncology, 15(Suppl. 3), iii157, 592P.
  • Glaspy, J., Henry, D., Patel, R., Tchekmedvian, S., Applebaum, S., Berdeaux, D., Lloyd, R., Berg, R., Austin, M., Rossi, G. & Darbepoetin Alfa 20010162 Study Group. (2005) Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. European Journal of Cancer, 41, 11401149.
  • Halstenson, C.E., Macres, M., Katz, S.A., Schnieders, J.R., Watanabe, M., Sobota, J.T. & Abraham, P.A. (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology and Therapeutics, 50, 702712.
  • Haselbeck, A., Reigner, B., Jordan, P., Pannier, A. & Glaspy, J. (2003) Pre-clinical and phase I pharmacokinetic and mode-of-action studies of C.E.R.A. (continuous erythropoiesis receptor activator), a novel erythropoietic agent with an extended serum half-life (abstract). Proceedings of the American Society of Clinical Oncology, 22, 748, 3006.
  • Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G., Littlewood, T.J. & Darbepoetin Alfa 20000161 Study Group. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394403.
  • Knight, K., Wade, S. & Balducci, L. (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. The American Journal of Medicine, 116(Suppl. 7A), 11S26S.
  • Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A.B., Rossi, G., Mackey, J. & Aranesp 980291 Study Group. (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39, 20262034.
  • Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E., Rapoport, B. & Epoetin Alfa Study Group. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 28652874.
  • Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., Gascon, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., Schneider, M. & Schrijvers, D. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer, 40, 22932306.
  • Macdougall, I.C. (2005) C.E.R.A. (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Current Hematology Reports, 4, 436440.
  • Morère, J.F. (2004) Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer, 46, 149156.
  • Moullet, I., Salles, G., Ketterer, N., Dumontet, C., Bouafia, F., Neidhart-Berard, E.M., Thieblemont, C., Felman, P. & Coiffier, B. (1998) Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Annals of Oncology, 9, 11091115.
  • Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., Messinger, D. & Epoetin Beta Hematology Study Group. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 24862494.
  • Österborg, A., Hellmann, A., Steegmann, J.L. & Couban, S. (2004) C.E.R.A. (Continuous Erythropoiesis Receptor Activator): dose-response trial of subcutaneous (SC) administration once every 3 weeks (Q3W) to patients with aggressive non-Hodgkin's lymphoma and anemia receiving chemotherapy (abstract). Blood, 104, 142b, 4225.
  • Reigner, B., Jordan, P., Pannier, A. & Glaspy, J. (2003) C.E.R.A. (continuous erythropoiesis receptor activator), a novel erythropoietic agent: dose-dependent response in phase I studies (abstract). Proceedings of the American Society of Clinical Oncology, 22, 732, 2943.
  • Thomas, M.L. (1998) Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Medical Oncology, 15(Suppl. 1), S3S7.